jueves, 8 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 21, 2025

Stock market today: Dow, S&P 500, Nasdaq bounce but end turbulent week with sharp losses

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq bounce but end turbulent week with sharp losses US stocks climbed on Friday to close a turbulent session in the green amid rising optimism for a December interest rate cut, while bitcoin (BTC-USD) kept tumbling amid a brutal stretch for cryptocurrencies…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Tech stocks still set for record $75 billion inflow in 2025

    80% confidence

  • Consumer sentiment deteriorated further in November to reading of 51

    80% confidence

  • After federal shutdown ended, sentiment lifted slightly from mid-month reading

    80% confidence

  • Oil prices to drop consistently through 2026 before picking back up in 2027

    80% confidence

  • Recent company hire did not take intellectual property from TSMC

    80% confidence

  • Q3 strength positions company well for holiday season and gives confidence to raise full year outlook

    80% confidence

  • He sees room for a rate cut in the near term

    80% confidence

  • Oil overhang to reach up to 4 million barrels per day in 2026

    80% confidence

Data points we hold from this source

Dow Jones Industrial Average · closing price46245.41 USD
Dow Jones Industrial Average · points change493.15 points
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Stock market today: Dow, S&P 500, Nasdaq bounce but end turbulent week with sharp losses — Source | Via News | es.VIA.NEWS